Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis.
OBJECTIVE
To report a case of a patient who experienced acute renal and hepatic toxicity following administration of daptomycin and review previously published case reports of renal and hepatic dysfunction with daptomycin.


METHODS
A 35-year-old man receiving daptomycin 4 mg/kg (275 mg) intravenously once daily (started 5 wk prior to presentation for presumed osteomyelitis) presented to the emergency department with elevations in serum creatinine and hepatic transaminase levels. He did not experience creatine kinase (CK) elevation or rhabdomyolysis. Following discontinuation of daptomycin, his renal and hepatic function improved.


CONCLUSIONS
To our knowledge, this is the first case of daptomycin-induced hepatotoxicity with acute renal failure in the absence of rhabdomyolysis and CK abnormalities. Previously published case reports described patients with a variety of elevations in liver function tests, serum creatinine, and CK with daptomycin. In our patient, the acute renal and hepatic toxicity was probable according to the Naranjo probability scale.


CONCLUSIONS
Although daptomycin is a well-tolerated antibacterial agent, clinicians should consider periodic monitoring of liver function and renal function tests to identify potential adverse effects.
Abraham
George
G
Department of Medicine, Saint Vincent Hospital, Worcester, MA, USA.
Finkelberg
Dmitry
D
Spooner
Linda M
LM
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000175:diagnosis; D000328:Adult; D056486:Chemical and Drug Induced Liver Injury; D017576:Daptomycin / Q000009:adverse effects*; D006801:Humans; D008107:Liver Diseases / Q000175:diagnosis; D008297:Male; D012206:Rhabdomyolysis / Q000175:diagnosis
D017576:Daptomycin